PropertyValue
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/ns/prov#value
  • Tarceva is currently approved in markets including Europe and the U.S. as first-line maintenance therapy for NSCLC patients and as a second-line treatment for advanced or metastatic NSCLC, irrespective of EGFR mutation status.
http://www.w3.org/ns/prov#wasQuotedFrom
  • genengnews.com